Noura Hajji, Ikram Khémiri
Laboratory of Mycology, Pathology & Biomarkers (LR16ES05), Department of Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Low Urin Tract Symptoms. 2025 Sep;17(5):e70024. doi: 10.1111/luts.70024.
The present study investigates the therapeutic potential of Cucurbita Pepo L. Seeds' Oil (CPSO) extracted by petroleum ether on testosterone-induced hyperplasia (BPH) in a castrated Wistar rat model.
Animals underwent two stages of treatment (28 days each): the testosterone treatment stage, to promote BPH, and the therapeutic stage, which consisted of an oral administration of CPSO. Forty-eight Wistar rats were equally divided into six groups: the negative control; groups 2-6 underwent a bilateral orchidectomy (induced via the scrotal route), then were redistributed into the castrated-control group and the castrated and testosterone-treated groups BPH induction (10 mg/kg). Twenty-eight days after BPH induction, the BPH rats were orally treated with Finasteride (FINA group: 5 mg/kg/d) and CPSO (CPSO-1 group: 40 mg/kg/d; CPSO-2 group: 80 mg/kg/d) for 28 additional days. Plasma biochemical parameters, circulating testosterone (T) and prostate-specific antigen (PSA), prostate oxidative markers, and inflammation were analyzed.
CPSO administration exhibited a decrease in prostate weight, normalized the plasma total proteins, lipids, calcium and glucose, testosterone, and PSA levels, and attenuated the disturbances of liver and kidney functions in BPH rats. At the prostate level, CPSO showed a notably decreased prostate oxidation and inflammation. The histological study showed that CPSO restored prostatic lesions caused by BPH.
According to the present results, we suggest that CPSO could have a protective potential related to its proven anti-oxidant, anti-hyperplastic, and anti-inflammatory properties on preventing testosterone-induced BPH in castrated rats and might be used as an herbal remedy or nutraceutical agent in BPH management.
本研究探讨石油醚提取的西葫芦籽精油(CPSO)对去势Wistar大鼠模型中睾酮诱导的增生(BPH)的治疗潜力。
动物接受两个治疗阶段(各28天):睾酮治疗阶段以促进BPH,治疗阶段包括口服CPSO。48只Wistar大鼠平均分为六组:阴性对照组;第2 - 6组进行双侧睾丸切除术(经阴囊途径诱导),然后重新分为去势对照组和去势并睾酮处理的BPH诱导组(10mg/kg)。BPH诱导28天后,对BPH大鼠口服非那雄胺(非那雄胺组:5mg/kg/d)和CPSO(CPSO - 1组:40mg/kg/d;CPSO - 2组:80mg/kg/d),持续28天。分析血浆生化参数、循环睾酮(T)和前列腺特异性抗原(PSA)、前列腺氧化标志物和炎症情况。
给予CPSO后,BPH大鼠的前列腺重量减轻,血浆总蛋白、脂质、钙和葡萄糖、睾酮及PSA水平恢复正常,肝肾功紊乱得到缓解。在前列腺水平,CPSO显示前列腺氧化和炎症明显减轻。组织学研究表明,CPSO可修复BPH引起的前列腺损伤。
根据目前的结果,我们认为CPSO因其已证实的抗氧化、抗增生和抗炎特性,可能对预防去势大鼠睾酮诱导的BPH具有保护潜力,可作为BPH管理中的草药或营养补充剂。